|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�Դ������� |
| ��������������� | |
|
���촺���� |
|
Ҷ��٫��У |
| PubMed | |
|
Article by |
|
Article by |
���ֳ����Դ����������о���״
���촺����, Ҷ��٫��У
������ҽ��ѧ����ҽԺƤ����
Ŀǰ÷�����ܲ������ܾ�������ס���ֳ���������ʪ�����ҹ������ļ�����Ҫ���Դ�������,�־������⼸�ּ��������в�ѧ����Ϸ��������Ƽ�Ԥ���ȷ�����о���״����չ�����˽��ܡ�
[2] Schmidt BL,Edjlalipour M,Luger A.Comparative evaluation of nine different enzyme-linked immunosorbent assays for determination of antibodies against Treponema pallidum in patients with primary syphilis.J Clin Microbiol,2000,38(3):1279-1282.
[3] Tabidze IL,Lee FK,Tambe P,et al.Enzyme-linked immunospot assay for the diagnosis of active Treponema pallidum infection during the various stages of svphilis.Sex Transm Dis,1999,26(8):426-430.
[4] Sato NS,Hirata MH,Hirata RD,et al.Analysis of Treponema pallidum recombinant antigens for diagnosis of syphilis by western blotting technique.Rev lnst Med Trop Sao Paulo,1999,41(2):115-118.
[5] Halling VW,Jones MF,Bestrom JE,et al.Clinical comparison of the Treponoma pallid pallidum CAPTIA syphilis-G enzyme immunoassay with the fluorescent trepemal antibody absorption immunoglobulin G assay for syphilis testing.J Clin Microbiol,1999,37(10):3233-3234.
[6] Pietravalle M,Pimpinelli F,Maini A,et al.Diagnostic relevance of polymerase chain reaction technology for T.pallidum in subjects with syphilis in different phases of infection.New Microbiol,1999,22(2):99-104.
[7] Jones CA,Knaup RC,Hayes M,et al.Urine.screening for gonococcal and chlamydial infections at community-based organizations in a high-morbidity area.Sex Transm Dis,2000,27(3):146-151.
[8] Shafer MA,Pantell RH,Schachter J.Is the routine pelvic examination needed with the advent of urine-based screening for sexually transmitted diseases? Arch Pediatr Adolesc Med,1999,153(2):119-125.
[9] Tapsall JW.Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region,1998.The WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme.Commun Dis Intell,2000,24(1):1-4.
[10] Tanaka M,Nakayama H,Haraoka M,et al.Autimimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan,1993 to 1998.J Clin Microbiol,2000,38(2):521-525.
[11] Paavonen J.Chlamydia trachomatis:A major cause of mucopurulent cervicitis and pelvic inflammatory disease in women.In:Elsner P,Eichmann A.sexually Transmitted Diseases:Advances in Diagnosis and Treament,New York:Karger,Basel,1996.110.
[12] Cheema MA,Rahman MU,Whittum-Hudson JA,et al.Cervical Chlamydia trachomatis in women at low risk for infection.Am J Med Sci,2000,319(2):123-125.
[13] Beebe JL,Gershman KA,Kelley JK,et al.Hov adequate is adequate for the collection of endocervical specimens for Chlamydia tracAomatis testing? Sex Transm Dis,1999,26(10):579-583.
[14] Borisov I,Nalbanski B,Filipov E,et al.The most suitable tests for studying chlamydial infection in women with sterility.Akush Ginekol Sofiia,1999,38(4):23-25.
[15] Hillis SD,Coles FB,Litchfield B,et al.Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women.A use-effectiveness study in public health settings.Sex Transm Dis,1998,25(1):5-11.
[16] McCormack WM,Dalu ZA,Martin DH,et al.Double-blind comparison of trovafloxacin and doxycycline in the treatment of uncomplicated chlamydial urethritis and cervicitis.Trovafloxacin chlamydial urethritis/cervicitisstudy group.Sex Transm Dis,1999,26(9):531-536.
[17] Kong F,Ma Z,James G,et al.Species identification and subtyping of Ureaplasma parvum and Ureaplasma urealyticum using PCR-based assays.J Clin Microbiol,2000,38 (3):1175-1179.
[18] Sonnex C,Strauss S,Gray JJ.Detection of human papillomavirus DNA on the fingers of patients with genital warts.Sex Transm Infect,1999,75(5):317-319.
[19] Boxman IL,Hogewoning A,Mulder LH,et al.Detection of human papillomavirus types 6 and 11 in pubic and perianal hair from patients with genital wats.J Clin Microbiol,1999,37(7):2270-2273.
[20] Trizna Z,Evans T,Bruce S,et al.A randomized phase �� study comparing four different interferon therapies in patients with recalcitrant condylomata acuminata.Sex Transm Dis,1998,25(7):361-365.
[21] Beutner KR,Spruance SL,Hougham,et al.Treatment of genital warts with an immune-response modifier (iniquimod).J Am Acad Dermatol,1998,38(2 Pt 1):230-239.
[22] Thompson HS,Davies ML,Holding Fl,et al.Phase I safety and antigenicity of TA-GW:a recombinant HPV6 L2E7 vaccine for the treatment of genital warts.Vaccine,1999,17(1):40-49.
[23] Scoular A,Kinghom G.British co-operative clinical group national survey on diagnostic issues surrounding genital herpes.MSSVD Special Interest Group on Genital Herpes and the British Co-operative Clinical Group.Sex Transm Infect,1999,75(6):403-405.
[24] Langenberg AG,Corey L,Ashley RL,et al.A prospective study of new infections with herpes simplex virus type I and type 2.Chiron HSV Vac-cine Study Group.N Engl J Med,1999,341(19):1432-1438.
[25] Puthavathana P,Kanyok R,Horthongkham N,et al.Prevalence of herpes simplex virus infection in patients suspected of genital herpes and virus typing by type specific fluorescent monoclonal antibodies.J Med Assoc Thai,1998,81(4):260-264.
[26] Madhavan HN,Priya K,Anand AR,et al.Detection of herpes simplex virus(HSV) genome using polymeraso chgin reaction (PCR) in clinical samples:comparison of PCR with standard laboratory methods for the detection of HSV.J Clin Virol2 1999,14(2):145-151.
[27] Liljeqvist JA,Svennerhoml B,Bergstrom T.Typing of clinical herpes simplex virus type I and type 2 isolates with monoclonal antibodies.J Clin Mi-crobiol,1999,37(8):2717-2718.
[28] Corey L,Langenberg AG,Ashley R,et al.Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection:two randomized controlled trials.Chiron HSV Vaccine Study Group.JAMA,1999,282(4):331-M0.